Anti-influenza immune plasma for the treatment of patients with severe influenza A: a randomised, double-blind, phase 3 trial

RCT (n=140) found that high-titre anti-influenza plasma was not superior to standard plasma for improved clinical status on day 7. Authors highlight that although a small clinically relevant effect could not be excluded, the benefit is insufficient to justify use.

Source: Current Awareness Service for Health (CASH) - October 3, 2019 Category: Consumer Health News Source Type: news